Cushman & Wakefield Ltd.
$5.17B- Market cap
- $3.21B
- Debt
- +$2.75B
- Cash
- −$784.20M
Capital structure 54% equity / 46% debt · EV / Revenue 0.50x · EV / EBITDA 9.77x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CWK stock price vs RCUS: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at RCUS's multiple
Needs RCUS P/E.
Implied fair value · at CWK's multiple
Needs EPS (TTM) is negative, CWK P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: CWK FY 2025 (ended Dec 31, 2025) · RCUS FY 2025 (ended Dec 31, 2025).
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 54% equity / 46% debt · EV / Revenue 0.50x · EV / EBITDA 9.77x
Capital structure 97% equity / 3% debt · EV / Revenue 14.79x
CWK carries the larger enterprise value at $5.17B against $3.65B; CWK trades on the lower EV / Revenue multiple (0.50x vs 14.79x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Cushman & Wakefield Ltd. · implied price per share
Bear
$1.12
Base
$2.79
Bull
$4.98
Arcus Biosciences, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.41x
0.16x
Net debt / EBITDA
Leverage against operating earnings
3.71x
0.36x
Cash and equivalents
Liquid reserves on the balance sheet
$784.20M
$222.00M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
$2.75B
$99.00M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.